drugset / Trial / NCT00380224

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

NCT00380224 ↗

Phase 3 Completed 120 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia. The study will compare the effect of these medications on several variables, including body weight and triglyceride levels.

Timeline

Start
2006-07
Primary completion
—
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bifeprunox Small molecule — —
Subject Olanzapine Small molecule — —

Indications